nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—CYP1A1—Dacarbazine—pancreatic cancer	0.0611	0.135	CbGbCtD
Bortezomib—CYP1A1—Tamoxifen—pancreatic cancer	0.0486	0.107	CbGbCtD
Bortezomib—CYP1A1—Erlotinib—pancreatic cancer	0.0413	0.0913	CbGbCtD
Bortezomib—CYP2C8—Tamoxifen—pancreatic cancer	0.0281	0.062	CbGbCtD
Bortezomib—CYP1A2—Dacarbazine—pancreatic cancer	0.0273	0.0603	CbGbCtD
Bortezomib—CYP2C8—Erlotinib—pancreatic cancer	0.0239	0.0527	CbGbCtD
Bortezomib—CYP2C19—Tamoxifen—pancreatic cancer	0.0235	0.052	CbGbCtD
Bortezomib—CYP1A2—Tamoxifen—pancreatic cancer	0.0217	0.048	CbGbCtD
Bortezomib—CYP2C8—Fluorouracil—pancreatic cancer	0.0207	0.0457	CbGbCtD
Bortezomib—CYP2C9—Tamoxifen—pancreatic cancer	0.0196	0.0432	CbGbCtD
Bortezomib—CYP1A2—Erlotinib—pancreatic cancer	0.0185	0.0408	CbGbCtD
Bortezomib—CYP2D6—Tamoxifen—pancreatic cancer	0.0179	0.0395	CbGbCtD
Bortezomib—CYP1A2—Fluorouracil—pancreatic cancer	0.016	0.0354	CbGbCtD
Bortezomib—CYP2D6—Erlotinib—pancreatic cancer	0.0152	0.0336	CbGbCtD
Bortezomib—CYP2C9—Fluorouracil—pancreatic cancer	0.0144	0.0319	CbGbCtD
Bortezomib—CYP3A4—Tamoxifen—pancreatic cancer	0.0114	0.0251	CbGbCtD
Bortezomib—CYP3A4—Erlotinib—pancreatic cancer	0.00968	0.0214	CbGbCtD
Bortezomib—CYP3A4—Irinotecan—pancreatic cancer	0.00874	0.0193	CbGbCtD
Bortezomib—CYP2D6—Doxorubicin—pancreatic cancer	0.00751	0.0166	CbGbCtD
Bortezomib—CYP3A4—Docetaxel—pancreatic cancer	0.0064	0.0141	CbGbCtD
Bortezomib—CYP3A4—Sunitinib—pancreatic cancer	0.00637	0.0141	CbGbCtD
Bortezomib—CYP3A4—Doxorubicin—pancreatic cancer	0.00477	0.0105	CbGbCtD
Bortezomib—PSMD1—islet of Langerhans—pancreatic cancer	0.00433	0.0871	CbGeAlD
Bortezomib—PSMD2—islet of Langerhans—pancreatic cancer	0.00383	0.0771	CbGeAlD
Bortezomib—PSMB8—islet of Langerhans—pancreatic cancer	0.00381	0.0767	CbGeAlD
Bortezomib—PSMB5—islet of Langerhans—pancreatic cancer	0.00337	0.0677	CbGeAlD
Bortezomib—PSMA1—digestive system—pancreatic cancer	0.0031	0.0623	CbGeAlD
Bortezomib—PSMD1—pancreas—pancreatic cancer	0.00304	0.0612	CbGeAlD
Bortezomib—PSMB1—islet of Langerhans—pancreatic cancer	0.00294	0.0592	CbGeAlD
Bortezomib—PSMB2—Azacitidine—Gemcitabine—pancreatic cancer	0.00293	1	CbGdCrCtD
Bortezomib—PSMB2—islet of Langerhans—pancreatic cancer	0.00287	0.0577	CbGeAlD
Bortezomib—PSMD2—pancreas—pancreatic cancer	0.0027	0.0542	CbGeAlD
Bortezomib—PSMB8—pancreas—pancreatic cancer	0.00268	0.0539	CbGeAlD
Bortezomib—PSMB5—pancreas—pancreatic cancer	0.00237	0.0476	CbGeAlD
Bortezomib—PSMD2—digestive system—pancreatic cancer	0.0023	0.0463	CbGeAlD
Bortezomib—PSMB1—pancreas—pancreatic cancer	0.00207	0.0416	CbGeAlD
Bortezomib—PSMB2—pancreas—pancreatic cancer	0.00202	0.0406	CbGeAlD
Bortezomib—PSMB1—digestive system—pancreatic cancer	0.00177	0.0355	CbGeAlD
Bortezomib—PSMB2—digestive system—pancreatic cancer	0.00172	0.0347	CbGeAlD
Bortezomib—SLC31A1—digestive system—pancreatic cancer	0.00149	0.03	CbGeAlD
Bortezomib—CYP2C19—digestive system—pancreatic cancer	0.000629	0.0127	CbGeAlD
Bortezomib—CYP1A2—digestive system—pancreatic cancer	0.000514	0.0103	CbGeAlD
Bortezomib—CYP1A1—digestive system—pancreatic cancer	0.000507	0.0102	CbGeAlD
Bortezomib—CYP2C9—digestive system—pancreatic cancer	0.000488	0.00981	CbGeAlD
Bortezomib—PTGS1—digestive system—pancreatic cancer	0.000445	0.00896	CbGeAlD
Bortezomib—CYP3A4—digestive system—pancreatic cancer	0.000372	0.00748	CbGeAlD
Bortezomib—CYP2D6—digestive system—pancreatic cancer	0.000366	0.00736	CbGeAlD
Bortezomib—Nateglinide—PPARG—pancreatic cancer	0.000277	1	CrCbGaD
Bortezomib—Urinary tract infection—Epirubicin—pancreatic cancer	5.81e-05	0.000193	CcSEcCtD
Bortezomib—Neutropenia—Doxorubicin—pancreatic cancer	5.8e-05	0.000193	CcSEcCtD
Bortezomib—Hypersensitivity—Fluorouracil—pancreatic cancer	5.77e-05	0.000192	CcSEcCtD
Bortezomib—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	5.77e-05	0.000191	CcSEcCtD
Bortezomib—Pollakiuria—Doxorubicin—pancreatic cancer	5.73e-05	0.00019	CcSEcCtD
Bortezomib—Asthenia—Gemcitabine—pancreatic cancer	5.71e-05	0.00019	CcSEcCtD
Bortezomib—Haematuria—Epirubicin—pancreatic cancer	5.7e-05	0.000189	CcSEcCtD
Bortezomib—Confusional state—Docetaxel—pancreatic cancer	5.7e-05	0.000189	CcSEcCtD
Bortezomib—Photosensitivity reaction—Doxorubicin—pancreatic cancer	5.66e-05	0.000188	CcSEcCtD
Bortezomib—Hepatobiliary disease—Epirubicin—pancreatic cancer	5.65e-05	0.000188	CcSEcCtD
Bortezomib—Oedema—Docetaxel—pancreatic cancer	5.65e-05	0.000188	CcSEcCtD
Bortezomib—Anaphylactic shock—Docetaxel—pancreatic cancer	5.65e-05	0.000188	CcSEcCtD
Bortezomib—Weight increased—Doxorubicin—pancreatic cancer	5.65e-05	0.000188	CcSEcCtD
Bortezomib—Epistaxis—Epirubicin—pancreatic cancer	5.64e-05	0.000187	CcSEcCtD
Bortezomib—Pruritus—Gemcitabine—pancreatic cancer	5.64e-05	0.000187	CcSEcCtD
Bortezomib—Infection—Docetaxel—pancreatic cancer	5.62e-05	0.000187	CcSEcCtD
Bortezomib—Weight decreased—Doxorubicin—pancreatic cancer	5.61e-05	0.000186	CcSEcCtD
Bortezomib—Sinusitis—Epirubicin—pancreatic cancer	5.61e-05	0.000186	CcSEcCtD
Bortezomib—Hyperglycaemia—Doxorubicin—pancreatic cancer	5.6e-05	0.000186	CcSEcCtD
Bortezomib—Diarrhoea—Irinotecan—pancreatic cancer	5.59e-05	0.000186	CcSEcCtD
Bortezomib—Pneumonia—Doxorubicin—pancreatic cancer	5.56e-05	0.000185	CcSEcCtD
Bortezomib—Shock—Docetaxel—pancreatic cancer	5.56e-05	0.000185	CcSEcCtD
Bortezomib—Nervous system disorder—Docetaxel—pancreatic cancer	5.54e-05	0.000184	CcSEcCtD
Bortezomib—Pruritus—Fluorouracil—pancreatic cancer	5.54e-05	0.000184	CcSEcCtD
Bortezomib—Thrombocytopenia—Docetaxel—pancreatic cancer	5.53e-05	0.000184	CcSEcCtD
Bortezomib—Infestation—Doxorubicin—pancreatic cancer	5.53e-05	0.000184	CcSEcCtD
Bortezomib—Infestation NOS—Doxorubicin—pancreatic cancer	5.53e-05	0.000184	CcSEcCtD
Bortezomib—Tachycardia—Docetaxel—pancreatic cancer	5.52e-05	0.000183	CcSEcCtD
Bortezomib—Skin disorder—Docetaxel—pancreatic cancer	5.49e-05	0.000182	CcSEcCtD
Bortezomib—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	5.48e-05	0.000182	CcSEcCtD
Bortezomib—Bradycardia—Epirubicin—pancreatic cancer	5.46e-05	0.000181	CcSEcCtD
Bortezomib—Diarrhoea—Gemcitabine—pancreatic cancer	5.45e-05	0.000181	CcSEcCtD
Bortezomib—Renal failure—Doxorubicin—pancreatic cancer	5.44e-05	0.000181	CcSEcCtD
Bortezomib—Neuropathy peripheral—Doxorubicin—pancreatic cancer	5.42e-05	0.00018	CcSEcCtD
Bortezomib—Dizziness—Irinotecan—pancreatic cancer	5.41e-05	0.00018	CcSEcCtD
Bortezomib—Haemoglobin—Epirubicin—pancreatic cancer	5.39e-05	0.000179	CcSEcCtD
Bortezomib—Stomatitis—Doxorubicin—pancreatic cancer	5.39e-05	0.000179	CcSEcCtD
Bortezomib—Anorexia—Docetaxel—pancreatic cancer	5.39e-05	0.000179	CcSEcCtD
Bortezomib—Conjunctivitis—Doxorubicin—pancreatic cancer	5.38e-05	0.000179	CcSEcCtD
Bortezomib—Urinary tract infection—Doxorubicin—pancreatic cancer	5.38e-05	0.000179	CcSEcCtD
Bortezomib—Haemorrhage—Epirubicin—pancreatic cancer	5.37e-05	0.000178	CcSEcCtD
Bortezomib—Hepatitis—Epirubicin—pancreatic cancer	5.37e-05	0.000178	CcSEcCtD
Bortezomib—Diarrhoea—Fluorouracil—pancreatic cancer	5.36e-05	0.000178	CcSEcCtD
Bortezomib—Hypoaesthesia—Epirubicin—pancreatic cancer	5.34e-05	0.000177	CcSEcCtD
Bortezomib—Urinary tract disorder—Epirubicin—pancreatic cancer	5.3e-05	0.000176	CcSEcCtD
Bortezomib—Oedema peripheral—Epirubicin—pancreatic cancer	5.29e-05	0.000176	CcSEcCtD
Bortezomib—Hypotension—Docetaxel—pancreatic cancer	5.28e-05	0.000175	CcSEcCtD
Bortezomib—Haematuria—Doxorubicin—pancreatic cancer	5.27e-05	0.000175	CcSEcCtD
Bortezomib—Connective tissue disorder—Epirubicin—pancreatic cancer	5.27e-05	0.000175	CcSEcCtD
Bortezomib—Urethral disorder—Epirubicin—pancreatic cancer	5.26e-05	0.000175	CcSEcCtD
Bortezomib—Hepatobiliary disease—Doxorubicin—pancreatic cancer	5.23e-05	0.000174	CcSEcCtD
Bortezomib—Epistaxis—Doxorubicin—pancreatic cancer	5.22e-05	0.000173	CcSEcCtD
Bortezomib—Vomiting—Irinotecan—pancreatic cancer	5.2e-05	0.000173	CcSEcCtD
Bortezomib—Sinusitis—Doxorubicin—pancreatic cancer	5.19e-05	0.000172	CcSEcCtD
Bortezomib—Dizziness—Fluorouracil—pancreatic cancer	5.18e-05	0.000172	CcSEcCtD
Bortezomib—Visual impairment—Epirubicin—pancreatic cancer	5.17e-05	0.000172	CcSEcCtD
Bortezomib—Rash—Irinotecan—pancreatic cancer	5.16e-05	0.000171	CcSEcCtD
Bortezomib—Dermatitis—Irinotecan—pancreatic cancer	5.15e-05	0.000171	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	5.15e-05	0.000171	CcSEcCtD
Bortezomib—Headache—Irinotecan—pancreatic cancer	5.12e-05	0.00017	CcSEcCtD
Bortezomib—Insomnia—Docetaxel—pancreatic cancer	5.11e-05	0.00017	CcSEcCtD
Bortezomib—Paraesthesia—Docetaxel—pancreatic cancer	5.08e-05	0.000169	CcSEcCtD
Bortezomib—Erythema multiforme—Epirubicin—pancreatic cancer	5.07e-05	0.000169	CcSEcCtD
Bortezomib—Vomiting—Gemcitabine—pancreatic cancer	5.06e-05	0.000168	CcSEcCtD
Bortezomib—Bradycardia—Doxorubicin—pancreatic cancer	5.05e-05	0.000168	CcSEcCtD
Bortezomib—Dyspnoea—Docetaxel—pancreatic cancer	5.04e-05	0.000167	CcSEcCtD
Bortezomib—Rash—Gemcitabine—pancreatic cancer	5.02e-05	0.000167	CcSEcCtD
Bortezomib—Dermatitis—Gemcitabine—pancreatic cancer	5.02e-05	0.000167	CcSEcCtD
Bortezomib—Eye disorder—Epirubicin—pancreatic cancer	5.02e-05	0.000167	CcSEcCtD
Bortezomib—Tinnitus—Epirubicin—pancreatic cancer	5e-05	0.000166	CcSEcCtD
Bortezomib—Haemoglobin—Doxorubicin—pancreatic cancer	4.99e-05	0.000166	CcSEcCtD
Bortezomib—Headache—Gemcitabine—pancreatic cancer	4.99e-05	0.000166	CcSEcCtD
Bortezomib—Cardiac disorder—Epirubicin—pancreatic cancer	4.98e-05	0.000165	CcSEcCtD
Bortezomib—Flushing—Epirubicin—pancreatic cancer	4.98e-05	0.000165	CcSEcCtD
Bortezomib—Vomiting—Fluorouracil—pancreatic cancer	4.98e-05	0.000165	CcSEcCtD
Bortezomib—Dyspepsia—Docetaxel—pancreatic cancer	4.98e-05	0.000165	CcSEcCtD
Bortezomib—Hepatitis—Doxorubicin—pancreatic cancer	4.97e-05	0.000165	CcSEcCtD
Bortezomib—Haemorrhage—Doxorubicin—pancreatic cancer	4.97e-05	0.000165	CcSEcCtD
Bortezomib—Hypoaesthesia—Doxorubicin—pancreatic cancer	4.94e-05	0.000164	CcSEcCtD
Bortezomib—Rash—Fluorouracil—pancreatic cancer	4.94e-05	0.000164	CcSEcCtD
Bortezomib—Dermatitis—Fluorouracil—pancreatic cancer	4.93e-05	0.000164	CcSEcCtD
Bortezomib—Decreased appetite—Docetaxel—pancreatic cancer	4.91e-05	0.000163	CcSEcCtD
Bortezomib—Headache—Fluorouracil—pancreatic cancer	4.91e-05	0.000163	CcSEcCtD
Bortezomib—Urinary tract disorder—Doxorubicin—pancreatic cancer	4.9e-05	0.000163	CcSEcCtD
Bortezomib—Oedema peripheral—Doxorubicin—pancreatic cancer	4.89e-05	0.000162	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Docetaxel—pancreatic cancer	4.88e-05	0.000162	CcSEcCtD
Bortezomib—Connective tissue disorder—Doxorubicin—pancreatic cancer	4.88e-05	0.000162	CcSEcCtD
Bortezomib—Fatigue—Docetaxel—pancreatic cancer	4.87e-05	0.000162	CcSEcCtD
Bortezomib—Angiopathy—Epirubicin—pancreatic cancer	4.87e-05	0.000162	CcSEcCtD
Bortezomib—Urethral disorder—Doxorubicin—pancreatic cancer	4.87e-05	0.000162	CcSEcCtD
Bortezomib—Nausea—Irinotecan—pancreatic cancer	4.86e-05	0.000161	CcSEcCtD
Bortezomib—Immune system disorder—Epirubicin—pancreatic cancer	4.85e-05	0.000161	CcSEcCtD
Bortezomib—Mediastinal disorder—Epirubicin—pancreatic cancer	4.84e-05	0.000161	CcSEcCtD
Bortezomib—Pain—Docetaxel—pancreatic cancer	4.83e-05	0.000161	CcSEcCtD
Bortezomib—Constipation—Docetaxel—pancreatic cancer	4.83e-05	0.000161	CcSEcCtD
Bortezomib—Chills—Epirubicin—pancreatic cancer	4.82e-05	0.00016	CcSEcCtD
Bortezomib—Arrhythmia—Epirubicin—pancreatic cancer	4.79e-05	0.000159	CcSEcCtD
Bortezomib—Visual impairment—Doxorubicin—pancreatic cancer	4.79e-05	0.000159	CcSEcCtD
Bortezomib—Nausea—Gemcitabine—pancreatic cancer	4.73e-05	0.000157	CcSEcCtD
Bortezomib—Mental disorder—Epirubicin—pancreatic cancer	4.7e-05	0.000156	CcSEcCtD
Bortezomib—Erythema multiforme—Doxorubicin—pancreatic cancer	4.69e-05	0.000156	CcSEcCtD
Bortezomib—Malnutrition—Epirubicin—pancreatic cancer	4.67e-05	0.000155	CcSEcCtD
Bortezomib—Erythema—Epirubicin—pancreatic cancer	4.67e-05	0.000155	CcSEcCtD
Bortezomib—Feeling abnormal—Docetaxel—pancreatic cancer	4.66e-05	0.000155	CcSEcCtD
Bortezomib—Nausea—Fluorouracil—pancreatic cancer	4.65e-05	0.000155	CcSEcCtD
Bortezomib—Eye disorder—Doxorubicin—pancreatic cancer	4.64e-05	0.000154	CcSEcCtD
Bortezomib—Tinnitus—Doxorubicin—pancreatic cancer	4.63e-05	0.000154	CcSEcCtD
Bortezomib—Gastrointestinal pain—Docetaxel—pancreatic cancer	4.62e-05	0.000154	CcSEcCtD
Bortezomib—Flushing—Doxorubicin—pancreatic cancer	4.61e-05	0.000153	CcSEcCtD
Bortezomib—Cardiac disorder—Doxorubicin—pancreatic cancer	4.61e-05	0.000153	CcSEcCtD
Bortezomib—Flatulence—Epirubicin—pancreatic cancer	4.6e-05	0.000153	CcSEcCtD
Bortezomib—Dysgeusia—Epirubicin—pancreatic cancer	4.57e-05	0.000152	CcSEcCtD
Bortezomib—Back pain—Epirubicin—pancreatic cancer	4.52e-05	0.00015	CcSEcCtD
Bortezomib—Angiopathy—Doxorubicin—pancreatic cancer	4.5e-05	0.00015	CcSEcCtD
Bortezomib—Muscle spasms—Epirubicin—pancreatic cancer	4.49e-05	0.000149	CcSEcCtD
Bortezomib—Immune system disorder—Doxorubicin—pancreatic cancer	4.48e-05	0.000149	CcSEcCtD
Bortezomib—Mediastinal disorder—Doxorubicin—pancreatic cancer	4.48e-05	0.000149	CcSEcCtD
Bortezomib—Body temperature increased—Docetaxel—pancreatic cancer	4.47e-05	0.000148	CcSEcCtD
Bortezomib—Abdominal pain—Docetaxel—pancreatic cancer	4.47e-05	0.000148	CcSEcCtD
Bortezomib—Chills—Doxorubicin—pancreatic cancer	4.46e-05	0.000148	CcSEcCtD
Bortezomib—Arrhythmia—Doxorubicin—pancreatic cancer	4.44e-05	0.000147	CcSEcCtD
Bortezomib—Vision blurred—Epirubicin—pancreatic cancer	4.4e-05	0.000146	CcSEcCtD
Bortezomib—Mental disorder—Doxorubicin—pancreatic cancer	4.35e-05	0.000144	CcSEcCtD
Bortezomib—Ill-defined disorder—Epirubicin—pancreatic cancer	4.33e-05	0.000144	CcSEcCtD
Bortezomib—Erythema—Doxorubicin—pancreatic cancer	4.32e-05	0.000144	CcSEcCtD
Bortezomib—Malnutrition—Doxorubicin—pancreatic cancer	4.32e-05	0.000144	CcSEcCtD
Bortezomib—Anaemia—Epirubicin—pancreatic cancer	4.32e-05	0.000143	CcSEcCtD
Bortezomib—Agitation—Epirubicin—pancreatic cancer	4.29e-05	0.000143	CcSEcCtD
Bortezomib—Flatulence—Doxorubicin—pancreatic cancer	4.26e-05	0.000141	CcSEcCtD
Bortezomib—Dysgeusia—Doxorubicin—pancreatic cancer	4.23e-05	0.000141	CcSEcCtD
Bortezomib—Malaise—Epirubicin—pancreatic cancer	4.21e-05	0.00014	CcSEcCtD
Bortezomib—Vertigo—Epirubicin—pancreatic cancer	4.2e-05	0.000139	CcSEcCtD
Bortezomib—Syncope—Epirubicin—pancreatic cancer	4.19e-05	0.000139	CcSEcCtD
Bortezomib—Leukopenia—Epirubicin—pancreatic cancer	4.18e-05	0.000139	CcSEcCtD
Bortezomib—Back pain—Doxorubicin—pancreatic cancer	4.18e-05	0.000139	CcSEcCtD
Bortezomib—Hypersensitivity—Docetaxel—pancreatic cancer	4.16e-05	0.000138	CcSEcCtD
Bortezomib—Muscle spasms—Doxorubicin—pancreatic cancer	4.16e-05	0.000138	CcSEcCtD
Bortezomib—Palpitations—Epirubicin—pancreatic cancer	4.13e-05	0.000137	CcSEcCtD
Bortezomib—Loss of consciousness—Epirubicin—pancreatic cancer	4.11e-05	0.000136	CcSEcCtD
Bortezomib—Cough—Epirubicin—pancreatic cancer	4.08e-05	0.000135	CcSEcCtD
Bortezomib—Vision blurred—Doxorubicin—pancreatic cancer	4.07e-05	0.000135	CcSEcCtD
Bortezomib—Asthenia—Docetaxel—pancreatic cancer	4.06e-05	0.000135	CcSEcCtD
Bortezomib—Convulsion—Epirubicin—pancreatic cancer	4.05e-05	0.000134	CcSEcCtD
Bortezomib—Hypertension—Epirubicin—pancreatic cancer	4.03e-05	0.000134	CcSEcCtD
Bortezomib—Ill-defined disorder—Doxorubicin—pancreatic cancer	4.01e-05	0.000133	CcSEcCtD
Bortezomib—Pruritus—Docetaxel—pancreatic cancer	4e-05	0.000133	CcSEcCtD
Bortezomib—Anaemia—Doxorubicin—pancreatic cancer	4e-05	0.000133	CcSEcCtD
Bortezomib—Chest pain—Epirubicin—pancreatic cancer	3.98e-05	0.000132	CcSEcCtD
Bortezomib—Arthralgia—Epirubicin—pancreatic cancer	3.98e-05	0.000132	CcSEcCtD
Bortezomib—Myalgia—Epirubicin—pancreatic cancer	3.98e-05	0.000132	CcSEcCtD
Bortezomib—Agitation—Doxorubicin—pancreatic cancer	3.97e-05	0.000132	CcSEcCtD
Bortezomib—Anxiety—Epirubicin—pancreatic cancer	3.96e-05	0.000132	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	3.95e-05	0.000131	CcSEcCtD
Bortezomib—Discomfort—Epirubicin—pancreatic cancer	3.93e-05	0.000131	CcSEcCtD
Bortezomib—Malaise—Doxorubicin—pancreatic cancer	3.9e-05	0.000129	CcSEcCtD
Bortezomib—Vertigo—Doxorubicin—pancreatic cancer	3.88e-05	0.000129	CcSEcCtD
Bortezomib—Syncope—Doxorubicin—pancreatic cancer	3.88e-05	0.000129	CcSEcCtD
Bortezomib—Leukopenia—Doxorubicin—pancreatic cancer	3.87e-05	0.000129	CcSEcCtD
Bortezomib—Diarrhoea—Docetaxel—pancreatic cancer	3.87e-05	0.000128	CcSEcCtD
Bortezomib—Confusional state—Epirubicin—pancreatic cancer	3.84e-05	0.000128	CcSEcCtD
Bortezomib—Palpitations—Doxorubicin—pancreatic cancer	3.82e-05	0.000127	CcSEcCtD
Bortezomib—Anaphylactic shock—Epirubicin—pancreatic cancer	3.81e-05	0.000127	CcSEcCtD
Bortezomib—Oedema—Epirubicin—pancreatic cancer	3.81e-05	0.000127	CcSEcCtD
Bortezomib—Loss of consciousness—Doxorubicin—pancreatic cancer	3.8e-05	0.000126	CcSEcCtD
Bortezomib—Infection—Epirubicin—pancreatic cancer	3.79e-05	0.000126	CcSEcCtD
Bortezomib—Cough—Doxorubicin—pancreatic cancer	3.77e-05	0.000125	CcSEcCtD
Bortezomib—Shock—Epirubicin—pancreatic cancer	3.75e-05	0.000125	CcSEcCtD
Bortezomib—Convulsion—Doxorubicin—pancreatic cancer	3.75e-05	0.000124	CcSEcCtD
Bortezomib—Nervous system disorder—Epirubicin—pancreatic cancer	3.74e-05	0.000124	CcSEcCtD
Bortezomib—Dizziness—Docetaxel—pancreatic cancer	3.74e-05	0.000124	CcSEcCtD
Bortezomib—Thrombocytopenia—Epirubicin—pancreatic cancer	3.73e-05	0.000124	CcSEcCtD
Bortezomib—Hypertension—Doxorubicin—pancreatic cancer	3.73e-05	0.000124	CcSEcCtD
Bortezomib—Tachycardia—Epirubicin—pancreatic cancer	3.72e-05	0.000124	CcSEcCtD
Bortezomib—Skin disorder—Epirubicin—pancreatic cancer	3.7e-05	0.000123	CcSEcCtD
Bortezomib—Hyperhidrosis—Epirubicin—pancreatic cancer	3.69e-05	0.000122	CcSEcCtD
Bortezomib—Myalgia—Doxorubicin—pancreatic cancer	3.68e-05	0.000122	CcSEcCtD
Bortezomib—Chest pain—Doxorubicin—pancreatic cancer	3.68e-05	0.000122	CcSEcCtD
Bortezomib—Arthralgia—Doxorubicin—pancreatic cancer	3.68e-05	0.000122	CcSEcCtD
Bortezomib—Anxiety—Doxorubicin—pancreatic cancer	3.67e-05	0.000122	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	3.65e-05	0.000121	CcSEcCtD
Bortezomib—Discomfort—Doxorubicin—pancreatic cancer	3.64e-05	0.000121	CcSEcCtD
Bortezomib—Anorexia—Epirubicin—pancreatic cancer	3.63e-05	0.000121	CcSEcCtD
Bortezomib—Vomiting—Docetaxel—pancreatic cancer	3.59e-05	0.000119	CcSEcCtD
Bortezomib—Rash—Docetaxel—pancreatic cancer	3.56e-05	0.000118	CcSEcCtD
Bortezomib—Hypotension—Epirubicin—pancreatic cancer	3.56e-05	0.000118	CcSEcCtD
Bortezomib—Dermatitis—Docetaxel—pancreatic cancer	3.56e-05	0.000118	CcSEcCtD
Bortezomib—Confusional state—Doxorubicin—pancreatic cancer	3.56e-05	0.000118	CcSEcCtD
Bortezomib—Headache—Docetaxel—pancreatic cancer	3.54e-05	0.000118	CcSEcCtD
Bortezomib—Oedema—Doxorubicin—pancreatic cancer	3.53e-05	0.000117	CcSEcCtD
Bortezomib—Anaphylactic shock—Doxorubicin—pancreatic cancer	3.53e-05	0.000117	CcSEcCtD
Bortezomib—Infection—Doxorubicin—pancreatic cancer	3.5e-05	0.000116	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	3.47e-05	0.000115	CcSEcCtD
Bortezomib—Shock—Doxorubicin—pancreatic cancer	3.47e-05	0.000115	CcSEcCtD
Bortezomib—Nervous system disorder—Doxorubicin—pancreatic cancer	3.46e-05	0.000115	CcSEcCtD
Bortezomib—Thrombocytopenia—Doxorubicin—pancreatic cancer	3.45e-05	0.000115	CcSEcCtD
Bortezomib—Insomnia—Epirubicin—pancreatic cancer	3.45e-05	0.000115	CcSEcCtD
Bortezomib—Tachycardia—Doxorubicin—pancreatic cancer	3.44e-05	0.000114	CcSEcCtD
Bortezomib—Skin disorder—Doxorubicin—pancreatic cancer	3.43e-05	0.000114	CcSEcCtD
Bortezomib—Paraesthesia—Epirubicin—pancreatic cancer	3.42e-05	0.000114	CcSEcCtD
Bortezomib—Hyperhidrosis—Doxorubicin—pancreatic cancer	3.41e-05	0.000113	CcSEcCtD
Bortezomib—Dyspnoea—Epirubicin—pancreatic cancer	3.4e-05	0.000113	CcSEcCtD
Bortezomib—Anorexia—Doxorubicin—pancreatic cancer	3.36e-05	0.000112	CcSEcCtD
Bortezomib—Nausea—Docetaxel—pancreatic cancer	3.36e-05	0.000112	CcSEcCtD
Bortezomib—Dyspepsia—Epirubicin—pancreatic cancer	3.36e-05	0.000111	CcSEcCtD
Bortezomib—Decreased appetite—Epirubicin—pancreatic cancer	3.31e-05	0.00011	CcSEcCtD
Bortezomib—Hypotension—Doxorubicin—pancreatic cancer	3.3e-05	0.000109	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Epirubicin—pancreatic cancer	3.29e-05	0.000109	CcSEcCtD
Bortezomib—Fatigue—Epirubicin—pancreatic cancer	3.29e-05	0.000109	CcSEcCtD
Bortezomib—Constipation—Epirubicin—pancreatic cancer	3.26e-05	0.000108	CcSEcCtD
Bortezomib—Pain—Epirubicin—pancreatic cancer	3.26e-05	0.000108	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	3.21e-05	0.000107	CcSEcCtD
Bortezomib—Insomnia—Doxorubicin—pancreatic cancer	3.19e-05	0.000106	CcSEcCtD
Bortezomib—Paraesthesia—Doxorubicin—pancreatic cancer	3.17e-05	0.000105	CcSEcCtD
Bortezomib—Dyspnoea—Doxorubicin—pancreatic cancer	3.15e-05	0.000104	CcSEcCtD
Bortezomib—Feeling abnormal—Epirubicin—pancreatic cancer	3.14e-05	0.000104	CcSEcCtD
Bortezomib—Gastrointestinal pain—Epirubicin—pancreatic cancer	3.12e-05	0.000104	CcSEcCtD
Bortezomib—Dyspepsia—Doxorubicin—pancreatic cancer	3.11e-05	0.000103	CcSEcCtD
Bortezomib—Decreased appetite—Doxorubicin—pancreatic cancer	3.07e-05	0.000102	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	3.05e-05	0.000101	CcSEcCtD
Bortezomib—Fatigue—Doxorubicin—pancreatic cancer	3.04e-05	0.000101	CcSEcCtD
Bortezomib—Urticaria—Epirubicin—pancreatic cancer	3.03e-05	0.000101	CcSEcCtD
Bortezomib—Pain—Doxorubicin—pancreatic cancer	3.02e-05	0.0001	CcSEcCtD
Bortezomib—Constipation—Doxorubicin—pancreatic cancer	3.02e-05	0.0001	CcSEcCtD
Bortezomib—Body temperature increased—Epirubicin—pancreatic cancer	3.01e-05	0.0001	CcSEcCtD
Bortezomib—Abdominal pain—Epirubicin—pancreatic cancer	3.01e-05	0.0001	CcSEcCtD
Bortezomib—Feeling abnormal—Doxorubicin—pancreatic cancer	2.91e-05	9.66e-05	CcSEcCtD
Bortezomib—Gastrointestinal pain—Doxorubicin—pancreatic cancer	2.88e-05	9.58e-05	CcSEcCtD
Bortezomib—Hypersensitivity—Epirubicin—pancreatic cancer	2.81e-05	9.33e-05	CcSEcCtD
Bortezomib—Urticaria—Doxorubicin—pancreatic cancer	2.8e-05	9.31e-05	CcSEcCtD
Bortezomib—Abdominal pain—Doxorubicin—pancreatic cancer	2.79e-05	9.26e-05	CcSEcCtD
Bortezomib—Body temperature increased—Doxorubicin—pancreatic cancer	2.79e-05	9.26e-05	CcSEcCtD
Bortezomib—Asthenia—Epirubicin—pancreatic cancer	2.74e-05	9.09e-05	CcSEcCtD
Bortezomib—Pruritus—Epirubicin—pancreatic cancer	2.7e-05	8.96e-05	CcSEcCtD
Bortezomib—Diarrhoea—Epirubicin—pancreatic cancer	2.61e-05	8.66e-05	CcSEcCtD
Bortezomib—Hypersensitivity—Doxorubicin—pancreatic cancer	2.6e-05	8.63e-05	CcSEcCtD
Bortezomib—Asthenia—Doxorubicin—pancreatic cancer	2.53e-05	8.41e-05	CcSEcCtD
Bortezomib—Dizziness—Epirubicin—pancreatic cancer	2.52e-05	8.37e-05	CcSEcCtD
Bortezomib—Pruritus—Doxorubicin—pancreatic cancer	2.5e-05	8.29e-05	CcSEcCtD
Bortezomib—Vomiting—Epirubicin—pancreatic cancer	2.42e-05	8.05e-05	CcSEcCtD
Bortezomib—Diarrhoea—Doxorubicin—pancreatic cancer	2.41e-05	8.02e-05	CcSEcCtD
Bortezomib—Rash—Epirubicin—pancreatic cancer	2.4e-05	7.98e-05	CcSEcCtD
Bortezomib—Dermatitis—Epirubicin—pancreatic cancer	2.4e-05	7.98e-05	CcSEcCtD
Bortezomib—Headache—Epirubicin—pancreatic cancer	2.39e-05	7.93e-05	CcSEcCtD
Bortezomib—Dizziness—Doxorubicin—pancreatic cancer	2.33e-05	7.75e-05	CcSEcCtD
Bortezomib—Nausea—Epirubicin—pancreatic cancer	2.26e-05	7.52e-05	CcSEcCtD
Bortezomib—Vomiting—Doxorubicin—pancreatic cancer	2.24e-05	7.45e-05	CcSEcCtD
Bortezomib—Rash—Doxorubicin—pancreatic cancer	2.22e-05	7.39e-05	CcSEcCtD
Bortezomib—Dermatitis—Doxorubicin—pancreatic cancer	2.22e-05	7.38e-05	CcSEcCtD
Bortezomib—Headache—Doxorubicin—pancreatic cancer	2.21e-05	7.34e-05	CcSEcCtD
Bortezomib—Nausea—Doxorubicin—pancreatic cancer	2.1e-05	6.96e-05	CcSEcCtD
Bortezomib—PSMA1—Signaling Pathways—EGFR—pancreatic cancer	7.74e-06	4.01e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CD44—pancreatic cancer	7.74e-06	4e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—EGFR—pancreatic cancer	7.71e-06	3.99e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CASP3—pancreatic cancer	7.69e-06	3.98e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CASP3—pancreatic cancer	7.69e-06	3.98e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CASP3—pancreatic cancer	7.69e-06	3.98e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—EGFR—pancreatic cancer	7.67e-06	3.97e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	7.62e-06	3.94e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—STK11—pancreatic cancer	7.61e-06	3.94e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	7.58e-06	3.92e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CASP3—pancreatic cancer	7.58e-06	3.92e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—APOE—pancreatic cancer	7.56e-06	3.91e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	7.51e-06	3.88e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CCND1—pancreatic cancer	7.48e-06	3.87e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CCND1—pancreatic cancer	7.48e-06	3.87e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CCND1—pancreatic cancer	7.48e-06	3.87e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GLP1R—pancreatic cancer	7.44e-06	3.85e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GCG—pancreatic cancer	7.42e-06	3.84e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CTNNB1—pancreatic cancer	7.41e-06	3.83e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CTNNB1—pancreatic cancer	7.41e-06	3.83e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CTNNB1—pancreatic cancer	7.41e-06	3.83e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CCND1—pancreatic cancer	7.38e-06	3.82e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—DPYD—pancreatic cancer	7.32e-06	3.79e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—KRAS—pancreatic cancer	7.32e-06	3.78e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CTNNB1—pancreatic cancer	7.3e-06	3.78e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—HRAS—pancreatic cancer	7.29e-06	3.77e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—HRAS—pancreatic cancer	7.29e-06	3.77e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—HRAS—pancreatic cancer	7.29e-06	3.77e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—KRAS—pancreatic cancer	7.28e-06	3.77e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—PIK3CA—pancreatic cancer	7.27e-06	3.76e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—PIK3CA—pancreatic cancer	7.27e-06	3.76e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—PIK3CA—pancreatic cancer	7.27e-06	3.76e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MMP9—pancreatic cancer	7.26e-06	3.76e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MMP9—pancreatic cancer	7.26e-06	3.76e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MMP9—pancreatic cancer	7.26e-06	3.76e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—KRAS—pancreatic cancer	7.25e-06	3.75e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—PTEN—pancreatic cancer	7.22e-06	3.74e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—PTEN—pancreatic cancer	7.22e-06	3.74e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—PTEN—pancreatic cancer	7.22e-06	3.74e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—HRAS—pancreatic cancer	7.19e-06	3.72e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—PIK3CA—pancreatic cancer	7.17e-06	3.71e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MMP9—pancreatic cancer	7.16e-06	3.7e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	7.15e-06	3.7e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	7.14e-06	3.69e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—TYMP—pancreatic cancer	7.13e-06	3.69e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PTEN—pancreatic cancer	7.12e-06	3.68e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	7.08e-06	3.66e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—STK11—pancreatic cancer	6.98e-06	3.61e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—SLC2A2—pancreatic cancer	6.95e-06	3.6e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CD44—pancreatic cancer	6.91e-06	3.57e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	6.88e-06	3.56e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CG—pancreatic cancer	6.82e-06	3.53e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	6.76e-06	3.5e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—HRAS—pancreatic cancer	6.73e-06	3.48e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—HRAS—pancreatic cancer	6.73e-06	3.48e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—HRAS—pancreatic cancer	6.73e-06	3.48e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—PIK3CA—pancreatic cancer	6.72e-06	3.48e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	6.7e-06	3.47e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—SRC—pancreatic cancer	6.7e-06	3.46e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—SRC—pancreatic cancer	6.7e-06	3.46e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—SRC—pancreatic cancer	6.7e-06	3.46e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—PIK3CA—pancreatic cancer	6.69e-06	3.46e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—PIK3CA—pancreatic cancer	6.66e-06	3.44e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	6.64e-06	3.43e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—HRAS—pancreatic cancer	6.64e-06	3.43e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GCG—pancreatic cancer	6.62e-06	3.43e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—SRC—pancreatic cancer	6.6e-06	3.42e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PPARG—pancreatic cancer	6.58e-06	3.4e-05	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—AKT1—pancreatic cancer	6.57e-06	3.4e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	6.55e-06	3.39e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—TYMS—pancreatic cancer	6.55e-06	3.39e-05	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—AKT1—pancreatic cancer	6.54e-06	3.38e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—VEGFA—pancreatic cancer	6.52e-06	3.37e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—VEGFA—pancreatic cancer	6.52e-06	3.37e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—VEGFA—pancreatic cancer	6.52e-06	3.37e-05	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—AKT1—pancreatic cancer	6.5e-06	3.37e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—pancreatic cancer	6.5e-06	3.36e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—pancreatic cancer	6.47e-06	3.35e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—STAT3—pancreatic cancer	6.46e-06	3.34e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—STAT3—pancreatic cancer	6.46e-06	3.34e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—STAT3—pancreatic cancer	6.46e-06	3.34e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—NRAS—pancreatic cancer	6.44e-06	3.33e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—NRAS—pancreatic cancer	6.44e-06	3.33e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—NRAS—pancreatic cancer	6.44e-06	3.33e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—pancreatic cancer	6.44e-06	3.33e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—AKT1—pancreatic cancer	6.44e-06	3.33e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—AKT1—pancreatic cancer	6.44e-06	3.33e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—AKT1—pancreatic cancer	6.44e-06	3.33e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—VEGFA—pancreatic cancer	6.43e-06	3.33e-05	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—AKT1—pancreatic cancer	6.4e-06	3.31e-05	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—AKT1—pancreatic cancer	6.4e-06	3.31e-05	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—AKT1—pancreatic cancer	6.4e-06	3.31e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—STAT3—pancreatic cancer	6.37e-06	3.29e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CD44—pancreatic cancer	6.35e-06	3.29e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—NRAS—pancreatic cancer	6.35e-06	3.29e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—AKT1—pancreatic cancer	6.35e-06	3.28e-05	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—AKT1—pancreatic cancer	6.31e-06	3.26e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CD44—pancreatic cancer	6.3e-06	3.26e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—STK11—pancreatic cancer	6.23e-06	3.22e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—HRAS—pancreatic cancer	6.22e-06	3.22e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—HRAS—pancreatic cancer	6.19e-06	3.2e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	6.17e-06	3.19e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—HRAS—pancreatic cancer	6.16e-06	3.19e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	6.11e-06	3.16e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—PIK3CA—pancreatic cancer	6.09e-06	3.15e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—PIK3CA—pancreatic cancer	6.09e-06	3.15e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—PIK3CA—pancreatic cancer	6.09e-06	3.15e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GCG—pancreatic cancer	6.09e-06	3.15e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	6.05e-06	3.13e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GCG—pancreatic cancer	6.04e-06	3.12e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—PIK3CA—pancreatic cancer	6.01e-06	3.11e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MYC—pancreatic cancer	6e-06	3.1e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MYC—pancreatic cancer	6e-06	3.1e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MYC—pancreatic cancer	6e-06	3.1e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—TYMS—pancreatic cancer	6e-06	3.1e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CD—pancreatic cancer	5.99e-06	3.1e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TGFB1—pancreatic cancer	5.99e-06	3.1e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TGFB1—pancreatic cancer	5.99e-06	3.1e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TGFB1—pancreatic cancer	5.99e-06	3.1e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—AKT1—pancreatic cancer	5.94e-06	3.07e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—AKT1—pancreatic cancer	5.94e-06	3.07e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—AKT1—pancreatic cancer	5.94e-06	3.07e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MYC—pancreatic cancer	5.92e-06	3.06e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TGFB1—pancreatic cancer	5.9e-06	3.05e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—EGFR—pancreatic cancer	5.87e-06	3.04e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—EGFR—pancreatic cancer	5.87e-06	3.04e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—EGFR—pancreatic cancer	5.87e-06	3.04e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—AKT1—pancreatic cancer	5.86e-06	3.03e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	5.84e-06	3.02e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—EGFR—pancreatic cancer	5.79e-06	2.99e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GLP1R—pancreatic cancer	5.75e-06	2.97e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—STK11—pancreatic cancer	5.73e-06	2.96e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—STK11—pancreatic cancer	5.68e-06	2.94e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—DPYD—pancreatic cancer	5.65e-06	2.92e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—KRAS—pancreatic cancer	5.54e-06	2.87e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—KRAS—pancreatic cancer	5.54e-06	2.87e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—KRAS—pancreatic cancer	5.54e-06	2.87e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—AKT1—pancreatic cancer	5.49e-06	2.84e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—KRAS—pancreatic cancer	5.47e-06	2.83e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—AKT1—pancreatic cancer	5.46e-06	2.83e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—AKT1—pancreatic cancer	5.44e-06	2.81e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CD44—pancreatic cancer	5.38e-06	2.78e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	5.36e-06	2.77e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—TYMS—pancreatic cancer	5.36e-06	2.77e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	5.33e-06	2.76e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—APOE—pancreatic cancer	5.32e-06	2.75e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	5.27e-06	2.73e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CB—pancreatic cancer	5.22e-06	2.7e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	5.22e-06	2.7e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTGS2—pancreatic cancer	5.18e-06	2.68e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GCG—pancreatic cancer	5.16e-06	2.67e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—PIK3CA—pancreatic cancer	5.09e-06	2.64e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—PIK3CA—pancreatic cancer	5.09e-06	2.64e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—PIK3CA—pancreatic cancer	5.09e-06	2.64e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	5.04e-06	2.61e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PIK3CA—pancreatic cancer	5.02e-06	2.6e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—AKT1—pancreatic cancer	4.98e-06	2.57e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—AKT1—pancreatic cancer	4.98e-06	2.57e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—AKT1—pancreatic cancer	4.98e-06	2.57e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—pancreatic cancer	4.93e-06	2.55e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—pancreatic cancer	4.93e-06	2.55e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—pancreatic cancer	4.93e-06	2.55e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—TYMS—pancreatic cancer	4.93e-06	2.55e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—AKT1—pancreatic cancer	4.91e-06	2.54e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—TYMS—pancreatic cancer	4.88e-06	2.53e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—APOE—pancreatic cancer	4.88e-06	2.52e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—pancreatic cancer	4.86e-06	2.51e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—STK11—pancreatic cancer	4.85e-06	2.51e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CG—pancreatic cancer	4.8e-06	2.49e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—HRAS—pancreatic cancer	4.71e-06	2.44e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—HRAS—pancreatic cancer	4.71e-06	2.44e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—HRAS—pancreatic cancer	4.71e-06	2.44e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—HRAS—pancreatic cancer	4.65e-06	2.4e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PPARG—pancreatic cancer	4.64e-06	2.4e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	4.62e-06	2.39e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	4.55e-06	2.36e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTEN—pancreatic cancer	4.51e-06	2.34e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CG—pancreatic cancer	4.4e-06	2.28e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—APOE—pancreatic cancer	4.36e-06	2.25e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PPARG—pancreatic cancer	4.25e-06	2.2e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CD—pancreatic cancer	4.22e-06	2.18e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—TYMS—pancreatic cancer	4.17e-06	2.16e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—AKT1—pancreatic cancer	4.16e-06	2.15e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—AKT1—pancreatic cancer	4.16e-06	2.15e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—AKT1—pancreatic cancer	4.16e-06	2.15e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CD44—pancreatic cancer	4.15e-06	2.15e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	4.12e-06	2.13e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—AKT1—pancreatic cancer	4.1e-06	2.12e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—APOE—pancreatic cancer	4.01e-06	2.07e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GCG—pancreatic cancer	3.98e-06	2.06e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—APOE—pancreatic cancer	3.97e-06	2.05e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CG—pancreatic cancer	3.93e-06	2.03e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CD—pancreatic cancer	3.87e-06	2e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PPARG—pancreatic cancer	3.79e-06	1.96e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	3.76e-06	1.94e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—STK11—pancreatic cancer	3.74e-06	1.94e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CB—pancreatic cancer	3.68e-06	1.9e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTGS2—pancreatic cancer	3.65e-06	1.89e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	3.62e-06	1.87e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CG—pancreatic cancer	3.58e-06	1.85e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PPARG—pancreatic cancer	3.49e-06	1.81e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PPARG—pancreatic cancer	3.46e-06	1.79e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CD—pancreatic cancer	3.46e-06	1.79e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—APOE—pancreatic cancer	3.39e-06	1.76e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CB—pancreatic cancer	3.37e-06	1.75e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTGS2—pancreatic cancer	3.34e-06	1.73e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—TYMS—pancreatic cancer	3.22e-06	1.67e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	3.21e-06	1.66e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CA—pancreatic cancer	3.18e-06	1.65e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTEN—pancreatic cancer	3.18e-06	1.65e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	3.18e-06	1.64e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CD—pancreatic cancer	3.15e-06	1.63e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	3.06e-06	1.58e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CB—pancreatic cancer	3.01e-06	1.56e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTGS2—pancreatic cancer	2.98e-06	1.54e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PPARG—pancreatic cancer	2.96e-06	1.53e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTEN—pancreatic cancer	2.92e-06	1.51e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	2.77e-06	1.43e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CB—pancreatic cancer	2.75e-06	1.42e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTGS2—pancreatic cancer	2.75e-06	1.42e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTGS2—pancreatic cancer	2.72e-06	1.41e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	2.69e-06	1.39e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—APOE—pancreatic cancer	2.62e-06	1.36e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTEN—pancreatic cancer	2.6e-06	1.35e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—AKT1—pancreatic cancer	2.6e-06	1.35e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTEN—pancreatic cancer	2.39e-06	1.24e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTEN—pancreatic cancer	2.37e-06	1.23e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	2.36e-06	1.22e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	2.35e-06	1.21e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTGS2—pancreatic cancer	2.33e-06	1.2e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PPARG—pancreatic cancer	2.28e-06	1.18e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CA—pancreatic cancer	2.24e-06	1.16e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	2.08e-06	1.08e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CA—pancreatic cancer	2.06e-06	1.06e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTEN—pancreatic cancer	2.03e-06	1.05e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CA—pancreatic cancer	1.84e-06	9.5e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—AKT1—pancreatic cancer	1.83e-06	9.48e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	1.81e-06	9.37e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTGS2—pancreatic cancer	1.79e-06	9.29e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	1.69e-06	8.74e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—AKT1—pancreatic cancer	1.68e-06	8.69e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CA—pancreatic cancer	1.67e-06	8.66e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTEN—pancreatic cancer	1.57e-06	8.1e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—AKT1—pancreatic cancer	1.5e-06	7.76e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	1.43e-06	7.4e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—AKT1—pancreatic cancer	1.38e-06	7.14e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—AKT1—pancreatic cancer	1.37e-06	7.08e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—AKT1—pancreatic cancer	1.17e-06	6.05e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	1.1e-06	5.71e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AKT1—pancreatic cancer	9.02e-07	4.67e-06	CbGpPWpGaD
